I was there as well and that is why they are looking to...

I was there as well and that is why they are looking to combination studies to see if they can improve on OS outcomes that will make the platform more competitive. Lesley also said that she felt the safety profile was better than the competition. I think the focus on Yuman's work in the presentation was more due to the fact that he was there in person rather than any despair about the B-cell platform since he wasn't part of that development. Agree with a relatively neutral perspective but very positive about the potential of the oncolytic virus platform and Oncarlytics.